Ascendis Pharma Wins FDA Accelerated Approval for YUVIWEL in Pediatric Achondroplasia
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ascendis Pharma ( (ASND) ) has provided an update.
On February 27, 2026, Ascendis Pharma announced that the U.S. Food & Drug Administration granted accelerated approval for YUVIWEL (navepegritide; developed as TransCon CNP), the first and only once-weekly treatment to increase linear growth in children aged two and older with achondroplasia with open epiphyses. The drug, a prodrug of C-type natriuretic peptide designed for continuous systemic exposure, addresses overactive FGFR3 signaling in this rare skeletal dysplasia, which is associated with muscular, neurological and cardiorespiratory complications.
The approval, supported by safety and efficacy data from three randomized, double-blind, placebo-controlled trials plus up to three years of extension data, was based on improvement in annualized growth velocity and remains contingent on confirmation of clinical benefit in follow-up studies. Ascendis expects to launch YUVIWEL in the U.S. in early second quarter 2026 with dedicated patient support through its Ascendis Signature Access Program and received a Rare Pediatric Disease Priority Review Voucher, enhancing its strategic position in rare pediatric disorders and potentially accelerating future product reviews.
The most recent analyst rating on (ASND) stock is a Buy with a $256.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.
Spark’s Take on ASND Stock
According to Spark, TipRanks’ AI Analyst, ASND is a Neutral.
The score is driven primarily by improving fundamentals (rapid revenue growth, strong margins, and a move to positive operating/free cash flow) but is held back by balance-sheet risk (negative equity and high debt) and unprofitable earnings (negative P/E). Technicals are neutral-to-slightly cautious, while the latest earnings call adds support via upbeat guidance and commercial/pipeline momentum despite elevated operating expenses and near-term volatility risks.
To see Spark’s full report on ASND stock, click here.
More about Ascendis Pharma
Ascendis Pharma A/S is a Denmark-based biopharmaceutical company focused on developing and commercializing therapies using its TransCon prodrug technology platform. The company targets serious rare diseases, including endocrine and skeletal disorders, and markets or develops long-acting therapies designed to improve treatment convenience and outcomes for patients worldwide.
Average Trading Volume: 729,054
Technical Sentiment Signal: Buy
Current Market Cap: $14.33B
Learn more about ASND stock on TipRanks’ Stock Analysis page.
